Meet the Team
CEO and Co-founder
Expertise in management, start-ups, operations, business development and product development.
Co-founded three stem cell technology companies, Pluristem (NASDAQ: PSTI), Brainstorm (NASDAQ: BCLI) and CellSource (CLCS.OB). He is involved as a consultant and co-founder with other start-ups in different fields.
Dr. Shay Tayeb
CTO and Co-founder
Postdoc graduate researcher and academic lecturer in the fields of molecular biology, microbiology, virology and gene therapy. Over the last decade, his research at the Hebrew University of Jerusalem has focused on understanding the tropism, host response, and mechanisms of action of Newcastle Disease Virus in several tumor models as well as human tissues. His work has led him to develop novel biological methods.
Certified Public Accountant and holds both a Bachelor’s degree in Sociology & Anthropology, and Accounting from Tel Aviv University as well as a Diploma in Business Administration – Finance from the University of Manchester. Served as CFO for Pfizer Israel and also for several private and public traded companies.
Dr. Christian Policard
Served as an executive of Sanofi -Synthelabo, a member of its board of directors (i.e. Sanofi Worldwide Executive Committee) and Chairman of Sanofi USA. He leads the Sanofi New Activities (Capital Development), responsible for most of Sanofi’s acquisitions and mergers. Previously, served as Vice President and Head of Applications at Pasteur Institute, overseeing the company’s business development activities.
Served as Head of Global Strategic Planning and Business Development of Pfizer Inc. Experienced general manager with a demonstrated expertise in market strategy, strategic planning, business development, organizational design/development and creative marketing. Managed global transformation programs and built organizations of 100+ personnel.
Dr. Asher Holtzer
Physicist by training. Serial entrepreneur with >30 years of senior leadership experience in the medical device industry, transitioning emerging technologies from research to clinical care, raising venture capital funds, taking companies public. Has served as director with both start-up and publicly traded companies including: InspireMD, TheraCoat, BioSig (USA), Magnetecs (USA), Adar, 2to3D, OSHIL., S.P. Market Windows, BioCube and others.
Scientific Advisory Board
Prof. Amos Panet
Professor of Virology, Hebrew University, Co-founder of two biotech companies.
Professor of Virology at the Hebrew University of Jerusalem since 1982, with more than 30 years of biotechnology research experience. Was the chief scientist and director of research at Bio-Technology General Corp, Israel. Cofounded two biotech companies based on his inventions: Medgenix, developing a novel biopump, and Theravir, developing an oncolytic virus. Has 21 registered patents.
Prof. Zichria Zakay-Rones
Professor of Virology, Hebrew University; Award–winning anti-cancer researcher.
Professor of Virology at the Hebrew University of Jerusalem since 1991, with more than 20 years of research experience in the field. Expertise in Newcastle Disease Virus vaccines and oncolytic activity (Kaye Innovations Award for Anti-Cancer Therapy 2008) and in vaccines and host immune responses, with special reference to influenza. Developed an intranasal flu vaccine that underwent clinical trials (Sarov Prize for Excellency in Human Microbiology, Israel Microbiology Society). Co-founded Theravir. Has 7 registered patents.
Dr. Corinne Szilagyi
Prof. Nir Peled
Prof Nir Peled is the Director of the Cancer Center at the Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel. He is board certified in internal medicine, pulmonology and medical oncology. He is one of the key opinion leaders in the field of lung cancer. He is the chair of the thoracic cancer Assembly of the European Thoracic Society and the co-chair of the screening committee of the IASLC (International Association of Lung Cancer). He is on the editorial board of the Journal of Thoracic Oncology and other lung-cancer related journals. Prof. Peled focuses on the wide translational and clinical perspectives of lung cancer and, including personalized targeted therapy in lung cancer, biomarkers development and early detection of this disease.
Business Advisory Board
Regulatory and Business Development Advisor
Extensive experience in early- and later-stage life science innovations, including negotiating and executing strategic Joint Ventures with leading players such as Pfizer, Johnson & Johnson, Galderma, Glaxo Smith Klein, Reckitt Benckiser, Medtronic, Respironics (Philips), and Covidien. Served as CEO, President, Chairman of the Board, Executive & non-Executive Board Director at public and private corporations, mainly in the USA.
Dr. Stephen Cherkez
Intellectual Property Advisory Board Member
Senior Vice President-intellectual property: B.Sc. in Chemical Engineering from the TechnionInstitute , M.Sc. and Ph.D. degrees in pharmaceutical chemistry from the Tel-Aviv University. Certified as registered patent agent. Was the Head of Teva’s Chemical Research, Founder and President of ChemAgis. In 1993 became VP Business Development of Agis and since 2003 held the double position of Perrigo International (Michigan) VP Intellectual Property and VP New Product Development. Authored or co-authored 33 patent families.